Is Aripiprazole (Abilify) Frequently Used in Inpatient Psychiatric Units?
Yes, aripiprazole is frequently used in inpatient psychiatric settings, with real-world data showing it is commonly prescribed across a range of psychiatric diagnoses including schizophrenia, bipolar disorder, and major depressive disorder.
Evidence from Inpatient Settings
Multiple studies document substantial use of aripiprazole in inpatient psychiatry:
A real-world German hospital-based study included 799 inpatients with schizophrenia treated with aripiprazole across 122 psychiatric hospitals 1, demonstrating widespread adoption in acute care settings.
A McLean Hospital analysis of 2,766 adult inpatients found 142 patients (5.1%) were prescribed aripiprazole during a 6-month period, with 83% continuing the medication at discharge 2. The drug was used across major affective disorders (52%), primary psychotic disorders (40%), and dementia (8%).
An elderly inpatient study identified 52 patients treated with aripiprazole over 3 years, with the most common diagnoses being schizophrenia/schizoaffective disorder (29%), bipolar disorder (25%), and major depressive disorder (23%) 3.
Clinical Context and Guidelines
While aripiprazole is FDA-approved for acute mania in adults and schizophrenia 4, guidelines for acute agitation management in emergency/inpatient settings primarily recommend other agents. The 2006 emergency department guidelines emphasize haloperidol, benzodiazepines, and other atypical antipsychotics like ziprasidone and olanzapine for acute agitation 5, with aripiprazole notably absent from these acute management algorithms.
However, aripiprazole appears in delirium management guidelines as a third-generation antipsychotic option 6, with a suggested starting dose of 5 mg PO or IM, noting it is less likely to cause extrapyramidal symptoms but may cause headache, agitation, anxiety, insomnia, and drowsiness.
Dosing Patterns in Inpatient Settings
Real-world inpatient dosing differs from outpatient maintenance:
- Mean doses in general adult inpatients: 16.1 ± 6.2 mg/day (0.20 ± 0.09 mg/kg) 2
- Elderly inpatients: median starting dose 5 mg, maximum 10 mg daily, with titration occurring over 3-4 days 3
- German hospital study: mean modal dose 15 mg/day (range 10-30 mg/day) for 4-week treatment periods 1
Safety Profile in Inpatient Use
Aripiprazole is generally well-tolerated in inpatient settings, though specific adverse effects warrant monitoring:
- Most common side effects: insomnia, irritability, restlessness, nausea, and behavioral activation 2, 1, 3
- Activation/agitation is particularly notable (8% in elderly inpatients 3, 15.5% overall adverse effect rate with three times higher risk in women 2)
- The FDA label documents akathisia as the most common adverse reaction in schizophrenia trials (8% vs 4% placebo) 7
Important Clinical Considerations
Aripiprazole's unique dopamine partial-agonist mechanism may cause behavioral activation, which can be problematic in acutely agitated patients. This likely explains why it is not featured in acute agitation protocols despite being commonly used for ongoing inpatient management of psychotic and mood disorders.
Body weight should be considered when dosing, as the McLean Hospital study found many obese patients received relatively low mg/kg doses, potentially leading to subtherapeutic treatment 2.
The drug requires several days to weeks for full therapeutic effect, making it more suitable for ongoing inpatient stabilization rather than immediate crisis intervention. The German study showed significant improvements in CGI, GAF, and SF-12 ratings within 4 weeks 1.